Soleno completes enrollment in PWS Study C602; Q2 net loss $8.5M

SOLENO THERAPEUTICS INC

Completed enrollment in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
Top-line data expected around end of Q3 2023; could support NDA submission to FDA.
Received $10M from SPA warrant exercise; cash and equivalents $19.4M as of June 30, 2023.
Net loss for Q2 2023 was $8.5M ($0.81 per share) vs $6.7M ($0.72 per share) in Q2 2022.
R&D expenses $5.1M in Q2 2023, up from $3.7M year-over-year due to clinical progress.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SOLENO THERAPEUTICS INC reported the second quarter ended June 30, 2023 results: net income $8.5 million, EPS $0.81.

Period: the second quarter ended June 30, 2023
Net income: $8.5 million
EPS: $0.81
Result: reported results

Exact text from the filing

Net loss for the three and six months ended June 30, 2023, was $8.5 million and $16.8 million, or a net loss of $0.81 and $1.69 per basic and diluted share

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

SOLENO THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-23-206255

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.